8-K: Autonomix Medical Announces Positive Results from Pancreatic Cancer Pain Trial, Initiates Market Expansion Study

Autonomix Medical reports positive outcomes from its first-in-human proof-of-concept trial for pancreatic cancer pain treatment and initiates a market expansion study for visceral cancer pain.

Summary

• Autonomix Medical announced positive results from the initial phase (PoC 1) of its first-in-human trial evaluating the safety and effectiveness of its technology for treating severe pancreatic cancer pain.
• The trial enrolled 20 patients and achieved key learnings, meeting all study objectives.
• The study demonstrated statistically significant pain relief as early as 24 hours post-procedure, with consistent positive results at 7 days and 4-6 weeks.
• 100% of responding patients achieved zero opioid use at 7 days post-procedure, and 73% remained opioid-free at 4-6 weeks.
• Based on these results, Autonomix is initiating a market expansion study (PoC 2) to include additional visceral cancers and earlier-stage pancreatic cancer.
• The PoC 2 phase aims to potentially double the addressable market beyond pancreatic cancer pain.
• The company's technology is a platform with potential applications in cardiology, hypertension, and chronic pain management.

Sentiment

Score: 8

Explanation: The document presents positive clinical trial results and outlines a clear path for future development, indicating a favorable outlook for the company.

Positives

• The PoC 1 trial achieved its objectives and provided key learnings.
• The study demonstrated statistically significant pain relief and improved quality of life for patients.
• A high percentage of responding patients were able to eliminate opioid use.
• The procedure showed a strong safety profile with no device or procedure-related serious adverse events.
• The company is expanding the study to address a broader range of visceral cancers and earlier-stage pancreatic cancer.

Negatives

• One patient was enrolled but not treated due to unsuccessful catheter placement because of an existing celiac trunk stenosis.
• Three patient VAS scores were not reported at the 4-6 week post-procedure follow-up due to the inability to travel given the natural progression of their disease and will be recorded as missing data in the final report.
• Three patients using brachial access showed no improvement in pain scores, representing a key procedural learning.

Risks

• The technology is investigational and has not yet been cleared for marketing in the United States.
• The forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially.
• The company's success depends on its ability to successfully enroll patients and complete its clinical studies.

Future Outlook

Autonomix plans to initiate U.S. trials in 2025, bringing the company closer to potential regulatory clearance and expanding the application of its technology to a broader range of visceral cancers and earlier-stage pancreatic cancers.

Management Comments

• 'We continue to be encouraged by the compelling results demonstrated in our PoC 1 phase, reinforced by consistent positive clinical outcomes observed at both the 7-day and 4-6 week post-procedure follow-ups,' said Brad Hauser, CEO of Autonomix.
• 'Based on the data to date, we believe our technology has the potential to address a broader range of visceral cancers that signal pain through the Celiac Plexus, as well as earlier stage pancreatic cancers, in a follow-on PoC 2 phase of the trial,' said Brad Hauser, CEO of Autonomix.
• 'The initial PoC 1 phase of the trial was a pivotal step in validating our approach that radiofrequency (RF) ablation can effectively block pain signals,' said Mr. Hauser.

Industry Context

The announcement positions Autonomix Medical within the growing field of interventional pain management, particularly for cancer-related pain. The focus on radiofrequency ablation and precision targeting aligns with trends towards less invasive and more effective pain relief solutions. Competitors in this space may include companies developing similar ablation technologies or alternative pain management therapies.

Comparison to Industry Standards

• It's difficult to compare Autonomix's results directly to industry standards without knowing the specific protocols and patient populations used in other trials.
• However, the reported pain reduction and opioid reduction rates appear promising compared to typical outcomes for patients with severe pancreatic cancer pain.
• Further comparison would require analyzing data from similar studies using VAS pain scales and opioid consumption metrics.
• Companies like Boston Scientific and Medtronic offer pain management solutions, but their approaches and target indications may differ from Autonomix's transvascular ablation method.

Stakeholder Impact

• Shareholders may benefit from the positive clinical trial results and the potential for market expansion.
• Patients with pancreatic and other visceral cancers may have access to a new and effective pain management option.
• The company's employees may benefit from the company's growth and success.
• The medical community may gain a new tool for treating chronic pain.

Next Steps

• Initiate the PoC 2 phase of the clinical trial, expanding to additional visceral cancers and earlier-stage pancreatic cancer.
• Gather additional interventional pain management information to inform future clinical studies.
• Plan U.S. trials in 2025 to pursue regulatory clearance.
• Continue developing the company's technology platform for applications in cardiology, hypertension, and chronic pain management.

Key Dates

Keywords

pancreatic cancer pain, visceral cancer pain, radiofrequency ablation, pain management, clinical trial, Autonomix Medical, PoC 1, PoC 2, opioid use, VAS pain scale